Management of Advanced Cutaneous Squamous Cell Carcinoma over the Last Decade: A Single-Centre Retrospective Study
Current Oncology · 27.07.2026 · 33 (8) · 449
DOI: 10.3390/curroncol33080449 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 27.07.2026. Verfasst von Ramon Staeger und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland. Hauptthemen laut MEDLINE: Cutaneous Squamous Cell Carcinoma, Skin Neoplasms, Carcinoma, Squamous Cell. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Cutaneous squamous cell carcinoma (cSCC) is one of the most common skin cancers, with a subset progressing to locally advanced (laSCC) or metastatic (mSCC) stages. The introduction of anti-PD1 immunotherapy has transformed treatment, but real-world data remain limited, particularly in immunosuppressed patients.
Methods
This single-centre, retrospective study included 189 patients with advanced cSCC treated between 2012 and 2022. Demographic, clinical, and treatment data were analyzed to assess clinical management and outcomes before and after the introduction of anti-PD1.
Results
Among the 189 patients, 72.5% were male, with a median age of 79 years. Overall, 86 patients presented with laSCC and 103 with mSCC. In 100 patients, a preceding primary cSCC was documented, and its complete resection (R0) was associated with significantly better overall survival (OS) after diagnosis of advanced disease (p < 0.001). Immunosuppressed patients, including organ transplant recipients and those with chronic lymphocytic leukemia (CLL), had significantly reduced OS (p = 0.017 and p = 0.0059, respectively). First-line treatment prior to 2018 predominantly involved surgery and radiotherapy. Following the introduction of anti-PD1 therapy, its use increased rapidly in both first- and second-line settings. From 2018 onward, the number of advanced cSCC cases discussed at the multidisciplinary tumorboard increased approximately threefold. Median OS was significantly longer for mSCC patients treated in the post-2018 era (p = 0.025), while the survival disadvantage of CLL patients compared to non-CLL patients widened, suggesting limited benefit from advances in systemic therapy in this subgroup. Best overall response to first-line anti-PD1 correlated significantly with OS, with complete responders achieving a 1-year progression-free survival of 83.3%.
Conclusions
The introduction of anti-PD1 has demonstrated improved survival outcomes in advanced cSCC, though significant challenges remain for immunosuppressed patients, particularly those with CLL and solid organ transplant recipients. Future research should focus on optimizing treatment for these high-risk groups, therapeutic sequencing, and the role of perioperative (neoadjuvant and adjuvant) immunotherapy strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland.
- Medical Faculty, University of Zurich, 8032 Zurich, Switzerland.
- Department of Dermatologie, Kantonsspital Aarau, 5000 Aarau, Switzerland.
ORCID-Profile: Ramon Staeger, Reinhard Dummer, Egle Ramelyte
Zitieren
APA
Staeger, R., Ehrat, L. G., Kamber, N., Dummer, R., Nägeli, M. C., & Ramelyte, E. (2026). Management of Advanced Cutaneous Squamous Cell Carcinoma over the Last Decade: A Single-Centre Retrospective Study. Current Oncology, 33(8), 449. https://doi.org/10.3390/curroncol33080449
Vancouver
Staeger R, Ehrat LG, Kamber N, Dummer R, Nägeli MC, Ramelyte E. Management of Advanced Cutaneous Squamous Cell Carcinoma over the Last Decade: A Single-Centre Retrospective Study. Current Oncology. 2026;33(8):449. doi:10.3390/curroncol33080449
BibTeX
@article{Staeger2026,
author = {Staeger, Ramon and Ehrat, Leandra Gioia and Kamber, Nicole and Dummer, Reinhard and Nägeli, Mirjam C and Ramelyte, Egle},
title = {Management of Advanced Cutaneous Squamous Cell Carcinoma over the Last Decade: A Single-Centre Retrospective Study},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {8},
pages = {449},
doi = {10.3390/curroncol33080449}
}
EUVIMED